1. Home
  2. PRPL vs TPST Comparison

PRPL vs TPST Comparison

Compare PRPL & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Purple Innovation Inc.

PRPL

Purple Innovation Inc.

SELL

Current Price

$2.27

Market Cap

13.9M

ML Signal

SELL

Logo Tempest Therapeutics Inc.

TPST

Tempest Therapeutics Inc.

HOLD

Current Price

$0.64

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRPL
TPST
Founded
2010
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.9M
13.7M
IPO Year
2015
2012

Fundamental Metrics

Financial Performance
Metric
PRPL
TPST
Price
$2.27
$0.64
Analyst Decision
Buy
Analyst Count
3
0
Target Price
★ $20.63
N/A
AVG Volume (30 Days)
44.1K
★ 2.1M
Earning Date
11-03-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 152.75
N/A
EPS
N/A
★ N/A
Revenue
★ $468,725,000.00
$295,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$7.50
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.28
$0.64
52 Week High
$10.00
$11.13

Technical Indicators

Market Signals
Indicator
PRPL
TPST
Relative Strength Index (RSI) 40.77 34.71
Support Level $0.36 N/A
Resistance Level $10.00 $1.24
Average True Range (ATR) 0.16 0.05
MACD 0.09 -0.01
Stochastic Oscillator 58.49 8.57

Price Performance

Historical Comparison
PRPL
TPST

About PRPL Purple Innovation Inc.

Purple Innovation Inc designs and manufactures sleep products. Using its GelFlex Grid technology, the company designs, manufactures, and offers branded comfort sleep products, including mattresses, pillows, cushions, mattress protectors, bases, sheets, and others. It markets and sells these products through direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.

About TPST Tempest Therapeutics Inc.

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Share on Social Networks: